Taking data science beyond company walls

Advancing oncology via machine learning-driven discovery and validation cycles requires more data than any one institution can gather alone, according to a panel of data scientists convened by BioCentury and Owkin. Accessing decentralized data through federated learning offers a path to more data liquidity, with privacy knobs that can be dialed up or down, depending on the use case.

In a March 22 webinar sponsored by precision medicine company Owkin Inc., panelists identified where they are seeing AI move the needle for cancer drug development, and what has made these applications successful...